Pharmacyclics (PCYC) Likely to See Upside Near-Term, Says RBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Roth Remains Positive on Pharmacyclics (PCYC) Following Imbruvica Update; Maintains 'Buy' Rating
January 14, 2015 7:52 AM ESTRoth Capital affirms Pharmacyclics (Nasdaq: PCYC) at Buy with a price target of $188 following an impressive update on... More
Baird Increasingly Bullish on Pharmacyclics (PCYC); Top Pick for 2015
January 13, 2015 8:04 AM ESTBaird analyst Brian Skorney reiterated an Outperform rating and $173 price target on Pharmacyclics (NASDAQ: PCYC) saying he is increasingly bullish on Imbruvica performance and 2015 guidance.
Skorney commented, "As one of our top picks for 2015, we anticipated that Pharmacyclics would continue to deliver on the... More
Pharmacyclics (PCYC) Sees FY15 Net Product Revenue of $1B for IMBRUVICA
January 12, 2015 5:46 PM ESTPharmacyclics, Inc. (NASDAQ: PCYC) today provided its preliminary unaudited 2014 U.S. net product revenue results and 2015 U.S. net product revenue outlook at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. For the fiscal year ended December 31, 2014, U.S. net product revenue for IMBRUVICA® (ibrutinib) is expected to be approximately $492 million. For the fourth quarter of 2014,... More
